Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8109929 | 0.80 | HDAC3 (0.55) | RAB9ANPC1CYP1A2NPSR1ALDH1A1 | |
| SCHEMBL1875367 | 0.79 | L3MBTL1 (0.73) | L3MBTL1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL1169578 | 0.78 | MLYCD (0.42) | L3MBTL1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL24512636 | 0.77 | RHOA (0.48) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15281239 | 0.77 | KMT2A (0.50) | L3MBTL1CYP2C9MLYCDMEN1KMT2A | |
| SCHEMBL712088 | 0.76 | L3MBTL1 (0.63) | L3MBTL1RAB9ANPC1SMN1; SMN2NPSR1 | |
| SCHEMBL1557170 | 0.76 | HDAC8 (0.53) | RAB9ANPC1MLYCD | |
| SCHEMBL323339 | 0.76 | CES2 (0.57) | NPSR1ALDH1A1MLYCDTP53MEN1 | |
| SCHEMBL20981664 | 0.75 | L3MBTL1 (0.82) | L3MBTL1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL10277409 | 0.75 | L3MBTL1 (0.61) | L3MBTL1RAB9ANPC1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305672-B1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9650371-B2 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20160326158-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160108052-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9273053-B2 | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150105379-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8637504-B2 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20110190279-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108052-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | L3MBTL1 378/4885RAB9A 1595/4885NPC1 1364/4885 |
| US-20160326158-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | L3MBTL1 369/4885RAB9A 1714/4885NPC1 1360/4885 |
| US-20150105379-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | L3MBTL1 378/4885RAB9A 1595/4885NPC1 1364/4885 |
| US-20110190279-A1 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY | BACE1, BACE2, APP | L3MBTL1 378/4885RAB9A 1595/4885NPC1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.